Below is what BBY said.
Note the first sentence-- a SINGLE successfull CAR-T product is valued at 0.12/sh. That doesn't place any value at all on all the other patented and pending products that belong to PAB. Yet the market values the entire company and assets including ~ 1.7cps cash at 2.7c. On this I remain bewildered, perhaps I should be in a home for the bewildered.
Column 1 Column 2 0
We value a single successful CAR-T product at A$0.12/sh. Separately, PAB remains on track to commence the Phase 1/2 trial of PAT-SM6 in combination with Amgen’s Kyprolis in multiple myeloma patients before the end of CY14. We retain our Speculative Buy recommendation and price target of A$0.12/sh.
Patrys BBY Research - Target 12c, page-6
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.229M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 38 | 43175478 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 10614841 | 12 |
View Market Depth
| Last trade - 16.12pm 01/11/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable